B-condition	0	9	Secondary
I-condition	10	18	leukemia
O	19	24	after
B-intervention	25	35	epirubicin
I-intervention	35	36	-
I-intervention	36	41	based
I-intervention	42	50	adjuvant
I-intervention	51	63	chemotherapy
O	64	66	in
B-eligibility	67	75	operable
I-eligibility	76	82	breast
I-eligibility	83	89	cancer
I-eligibility	90	98	patients
O	98	99	:
O	100	102	16
O	103	108	years
O	109	119	experience
O	120	122	of
O	123	126	the
B-location	127	133	French
O	134	142	Adjuvant
O	143	148	Study
O	149	154	Group
O	154	155	.

O	156	159	The
O	160	167	purpose
O	168	170	of
O	171	175	this
O	176	181	study
O	182	185	was
O	186	188	to
O	189	197	evaluate
O	198	207	incidence
O	208	211	and
O	212	216	risk
O	217	224	factors
O	225	227	of
O	228	237	secondary
O	238	246	leukemia
O	247	252	after
O	253	261	adjuvant
O	262	272	epirubicin
O	272	273	-
O	273	278	based
O	279	291	chemotherapy
O	292	294	in
O	295	301	breast
O	302	308	cancer
O	309	317	patients
O	317	318	.

O	319	324	Among
O	325	330	eight
O	331	337	French
O	338	346	Adjuvant
O	347	352	Study
O	353	358	Group
O	359	365	trials
O	365	366	,
B-total-participants	367	371	3653
O	372	380	patients
O	381	385	were
O	386	396	assessable
O	396	397	:
B-intervention-participants	398	402	2603
O	403	411	received
O	412	422	epirubicin
O	422	423	;
B-intervention-participants	424	427	682
O	428	436	received
B-intervention	437	451	hormonotherapy
O	451	452	;
O	453	456	and
B-control-participants	457	460	368
O	461	464	had
B-control	465	467	no
I-control	468	476	systemic
I-control	477	486	treatment
O	486	487	.

O	488	500	Chemotherapy
O	501	504	was
O	505	508	FEC
O	509	516	regimen
O	517	519	in
O	520	522	85
O	522	523	%
O	524	526	of
O	527	532	cases
O	533	534	(
O	534	546	fluorouracil
O	547	550	500
O	551	553	mg
O	553	554	/
O	554	556	m2
O	556	557	,
O	558	568	epirubicin
O	569	571	50
O	571	572	,
O	573	575	75
O	576	578	or
O	579	582	100
O	583	585	mg
O	585	586	/
O	586	588	m2
O	588	589	,
O	590	606	cyclophosphamide
O	607	610	500
O	611	613	mg
O	613	614	/
O	614	616	m2
O	616	617	,
O	618	623	three
O	624	626	or
O	627	630	six
O	631	637	cycles
O	637	638	)
O	638	639	.

O	640	650	Epirubicin
O	651	661	cumulative
O	662	666	dose
O	667	670	was
O	671	672	<
O	672	675	300
O	676	678	mg
O	678	679	/
O	679	681	m2
O	682	684	in
O	685	689	1045
O	690	698	patients
O	698	699	;
O	700	703	300
O	703	704	-
O	704	707	600
O	708	710	mg
O	710	711	/
O	711	713	m2
O	714	716	in
O	717	721	1187
O	721	722	;
O	723	726	and
O	727	728	>
O	729	731	or
O	732	733	=
O	733	736	600
O	737	739	mg
O	739	740	/
O	740	742	m2
O	743	745	in
O	746	749	286
O	749	750	,
O	751	759	followed
O	760	762	by
O	763	775	radiotherapy
O	776	778	in
O	779	781	96
O	781	782	%
O	783	785	of
O	786	791	cases
O	791	792	.

O	793	796	The
O	797	803	median
O	804	810	follow
O	810	811	-
O	811	813	up
O	814	817	was
O	818	821	104
O	822	828	months
O	828	829	.

B-iv-bin-abs	830	835	Eight
B-outcome	836	841	cases
I-outcome	842	844	of
I-outcome	845	853	leukemia
O	854	862	occurred
O	863	865	in
O	866	876	epirubicin
O	876	877	-
O	877	884	exposed
O	885	893	patients
O	894	897	and
B-cv-bin-abs	898	901	one
O	902	904	in
O	905	908	non
O	908	909	-
O	909	916	exposed
O	917	925	patients
O	925	926	.

O	927	932	After
O	933	934	9
O	935	940	years
O	940	941	,
O	942	945	the
B-outcome	946	950	risk
I-outcome	951	953	of
I-outcome	954	964	developing
I-outcome	965	966	a
I-outcome	967	975	leukemia
O	976	979	was
B-iv-bin-percent	980	981	0
I-iv-bin-percent	981	982	.
I-iv-bin-percent	982	984	34
I-iv-bin-percent	984	985	%
O	986	987	(
O	987	989	95
O	989	990	%
O	991	1001	confidence
O	1002	1010	interval
O	1011	1012	0
O	1012	1013	.
O	1013	1015	11
O	1015	1016	-
O	1016	1017	0
O	1017	1018	.
O	1018	1020	57
O	1020	1021	)
O	1022	1024	in
O	1025	1035	epirubicin
O	1035	1036	-
O	1036	1043	exposed
O	1044	1052	patients
O	1052	1053	.

O	1054	1056	In
O	1057	1065	patients
O	1066	1075	receiving
O	1076	1088	chemotherapy
O	1088	1089	,
B-outcome	1090	1098	leukemia
I-outcome	1099	1107	subtypes
O	1108	1112	were
O	1112	1113	:
B-outcome	1114	1118	AML2
O	1119	1120	(
B-iv-bin-percent	1120	1123	two
O	1123	1124	)
O	1124	1125	,
B-outcome	1126	1130	AML3
O	1131	1132	(
B-iv-bin-abs	1132	1135	one
O	1135	1136	)
O	1136	1137	,
B-outcome	1138	1142	AML4
O	1143	1144	(
B-iv-bin-abs	1144	1149	three
O	1149	1150	)
O	1151	1154	and
B-outcome	1155	1158	ALL
O	1159	1160	(
B-iv-bin-abs	1160	1163	two
O	1163	1164	)
O	1164	1165	.

O	1166	1170	None
O	1171	1173	of
O	1174	1177	the
O	1178	1189	classically
O	1190	1200	recognized
O	1201	1205	risk
O	1206	1213	factors
O	1214	1217	was
O	1218	1231	significantly
O	1232	1242	correlated
O	1243	1247	with
O	1248	1251	the
O	1252	1262	occurrence
O	1263	1265	of
O	1266	1267	a
O	1268	1276	leukemia
O	1276	1277	.

O	1278	1290	Irrespective
O	1291	1293	of
O	1294	1297	the
O	1298	1302	dose
O	1302	1303	,
O	1304	1307	the
B-outcome	1308	1317	incidence
I-outcome	1318	1320	of
I-outcome	1321	1330	secondary
I-outcome	1331	1339	leukemia
O	1340	1345	after
O	1346	1354	adjuvant
O	1355	1365	epirubicin
O	1365	1366	-
O	1366	1371	based
O	1372	1384	chemotherapy
O	1385	1388	was
O	1389	1392	low
O	1392	1393	.

O	1394	1399	After
O	1400	1401	a
O	1402	1406	long
O	1407	1413	follow
O	1413	1414	-
O	1414	1416	up
O	1416	1417	,
O	1418	1421	the
O	1422	1429	benefit
O	1429	1430	/
O	1430	1434	risk
O	1435	1440	ratio
O	1441	1444	for
O	1445	1450	early
O	1451	1457	breast
O	1458	1464	cancer
O	1465	1473	patients
O	1474	1482	remained
O	1483	1485	in
O	1486	1491	favor
O	1492	1494	of
O	1495	1505	epirubicin
O	1505	1506	-
O	1506	1511	based
O	1512	1520	adjuvant
O	1521	1533	chemotherapy
O	1533	1534	:
O	1535	1540	eight
O	1541	1546	cases
O	1547	1548	(
O	1548	1549	0
O	1549	1550	.
O	1550	1552	31
O	1552	1553	%
O	1553	1554	)
O	1555	1563	occurred
O	1563	1564	,
O	1565	1568	and
O	1569	1571	in
O	1572	1576	some
O	1577	1579	of
O	1580	1584	them
O	1584	1585	,
O	1586	1595	treatment
O	1596	1605	causality
O	1606	1611	could
O	1612	1614	be
O	1615	1624	debatable
O	1624	1625	.
